Skip to main content
METABIOMED.CO.,LTD logo

METABIOMED.CO.,LTD — Investor Relations & Filings

Ticker · 059210 ISIN · KR7059210005 KO Manufacturing
Open in API
Filings indexed 217 across all filing types
Latest filing 2025-03-31 Declaration of Voting R…
Country KR South Korea
Listing KO 059210

About METABIOMED.CO.,LTD

https://www.meta-biomed.com/

METABIOMED.CO.,LTD. is a developer and manufacturer of medical devices and biomaterials. The company's operations are organized into four primary business areas: Dental, Suture Material & Biomaterial, Meta Surgical, and Cosmetic Medical. Its dental division provides a range of equipment and materials, with its root canal filling product holding the largest global market share. The company also manufactures various synthetic absorbable surgical sutures, including Poliglecaprone (PGCL) and Polydioxanone (PDO) types. The surgical division offers devices for use in general surgery, orthopedics, neurosurgery, and obstetrics & gynecology. In the cosmetic medical field, it produces products such as PDO threads. METABIOMED distributes its products to over 100 countries through a global sales network.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official filing titled '정기주주총회결과' (Results of the Annual General Meeting) for Meta Biomed. It details the outcomes of the meeting held on 2025-03-31, including the approval of financial statements, dividend declarations, and board/auditor compensation limits. This aligns perfectly with the definition of a Declaration of Voting Results (DVA), which covers official results from shareholder votes at general meetings.
2025-03-31 Korean
[기재정정]사업보고서 (2024.12)
Annual Report Classification · 100% confidence The document is a '사업보고서' (Business Report), which is the Korean equivalent of an Annual Report (10-K). It covers the fiscal year from January 1, 2024, to December 31, 2024, and includes detailed sections on company overview, history, capital changes, and financial information. The document also includes a '정정신고' (Correction Report) header, indicating it is an amendment to the previously filed annual report, which is standard practice for 10-K filings. FY 2024
2025-03-27 Korean
신규시설투자등
Regulatory Filings Classification · 100% confidence The document is a regulatory disclosure regarding a 'New Facility Investment' (신규시설투자) by Meta Biomed. It details the investment amount, purpose (R&D and manufacturing facility construction), duration, and board approval status. This type of disclosure regarding capital expenditure and facility investment falls under general regulatory filings as it does not fit into specific categories like M&A, share issues, or financial reports.
2025-03-21 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Meta Biomed titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, revenue, profit), and auditor information. While it contains financial data, it is a standard regulatory disclosure announcement in the Korean market (DART/KIND system) notifying the public that the audit report has been submitted, rather than the full annual report document itself. Therefore, it is classified as a Report Publication Announcement (RPA). FY 2024
2025-03-21 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Meta Biomed Co., Ltd. for the fiscal year ending December 31, 2024. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. It is not an Annual Report (10-K) as it focuses specifically on the audit results and financial statements rather than the broader narrative of an annual report, and it is not an announcement (RPA) because it contains the full financial data. FY 2024
2025-03-21 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Proxy Solicitation Reference Document) and contains detailed information regarding the upcoming Annual General Meeting (AGM) of Meta Biomed, including the agenda, voting procedures, and proxy solicitation details. It also includes preliminary financial statements for the 26th fiscal year. This document is a standard proxy statement used to solicit shareholder votes for an AGM.
2025-03-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.